Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesDividends payablesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Envoy Medical (COCH) Cash & Equivalents (2022 - 2025)

Envoy Medical's Cash & Equivalents history spans 4 years, with the latest figure at $3.6 million for Q3 2025.

  • For Q3 2025, Cash & Equivalents fell 19.62% year-over-year to $3.6 million; the TTM value through Sep 2025 reached $3.6 million, down 19.62%, while the annual FY2024 figure was $5.5 million, 29.99% up from the prior year.
  • Cash & Equivalents for Q3 2025 was $3.6 million at Envoy Medical, down from $5.3 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $16.8 million in Q3 2023 and bottomed at $68000.0 in Q2 2023.
  • The 4-year median for Cash & Equivalents is $4.2 million (2023), against an average of $4.1 million.
  • The largest annual shift saw Cash & Equivalents tumbled 85.74% in 2023 before it soared 2467.65% in 2024.
  • A 4-year view of Cash & Equivalents shows it stood at $183000.0 in 2022, then surged by 2204.92% to $4.2 million in 2023, then rose by 29.99% to $5.5 million in 2024, then plummeted by 35.14% to $3.6 million in 2025.
  • Per Business Quant, the three most recent readings for COCH's Cash & Equivalents are $3.6 million (Q3 2025), $5.3 million (Q2 2025), and $5.3 million (Q1 2025).